Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Advanced Platelet-Rich Fibrin Plus (A-PRF+) is a third-generation autologous platelet concentrate (APC) produced through a specific low-speed centrifugation concept (LSCC). By utilizing lower g-forces and shorter centrifugation times compared to traditional Leukocyte- and Platelet-Rich Fibrin (L-PRF), the A-PRF+ protocol results in a fibrin scaffold with increased porosity and a more homogenous distribution of white blood cells and platelets. This matrix acts as a bioactive reservoir that slowly releases essential growth factors, including Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), and Transforming Growth Factor beta (TGF-β). A-PRF+ is primarily utilized in regenerative dentistry and oral surgery to promote angiogenesis, tissue epithelialization, and stem cell proliferation. It is frequently employed for the revascularization of necrotic immature permanent teeth, socket preservation, alveolar ridge augmentation, and the management of gingival recessions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on advanced platelet-rich fibrin plus.